Stocks to watch

WOW - WOOLWORTHS - down 91 cents, or 2.71 per cent, to $32.70

After six straight weeks of gains, shares in the supermarket chain have started to come back down to earth. Woolworths was down 4.33 per cent for the week.

SYD - SYDNEY AIRPORT - up 10 cents, or 1.33 per cent, to $7.61

Sydney Airport shares gained altitude after it dodged a stand-off over worker pay, despite flagging subdued growth in passenger numbers for the rest of the year.

EHE - ESTIA HEALTH - down nine cents, or three per cent, to $2.90

The aged care operator flagged that its full-year earnings would likely come in at around $82 million to $94 million, an increase from last year but lower than previously anticipated.

"Across the portfolio, occupancy has been impacted by continuing adverse publicity in the sector and influenza in South Australia," Estia said.

Estia said it expected to spend $2.3 million responding to a royal commission into aged care, and routine interactions with a new industry regulator will involve expenses in staff and external support.

RCT - REEF CASINO TRUST - down 11 cents, or 3.68 per cent, to $2.88

The owner and lessor of the Reef Hotel Casino complex in Cairns said its distributable profit for the first half of the year will be from $1.2 million to $1.7 million, compared to the $1.7 million to $3 million figure forecast in April.

The trust blamed by Cairns' extraordinary wet season over the summer, a subdued local and national economy and fewer Chinese visitors.

AKP - AUDIO PIXELS - down $1.62, or 8.1 per cent, to $18.37

The Israeli audio company said it suffered a setback in its quest to build a revolutionary new type of speaker "when a rare system glitch in the prober resulted in the destruction of the wafer".

The company has ordered replacement wafers from its vendor.

SPL - STARPHARMA - up 0.5 cents, or 0.39 per cent, to $1.29

The Melbourne biotech company said its nanoparticle formulation showed "impressive" results in treating colorectal cancer in mice implanted with human cancer cells, a well-established means of assessing the effectiveness of anti-cancer therapies.

Human trials of the drug, DEP irinotecan, are expected to start mid-year.

Austrlaian Associated PressBack to Breaking News

  • Print this page
  • Copy Link